Table 1:
Participant characteristics
| Characteristic | PLWH (n=99) | Controls (n=152) |
|---|---|---|
| HIV-related variables | ||
| Receiving antiretroviral therapy, n (%) | 99 (100%) | - |
| Most recent plasma viral load, copies HIV RNA/mL, median [IQR] | <50 [<50 - <50] | - |
| Most recent CD4+ T-cell count in cells/mm3, median [IQR] | 715 [545–943] | - |
| Nadir CD4+ T-cell count in cells/mm3, median [IQR] | 280 [123–490] | - |
| Sociodemographic and health variables | ||
| Age in years, median [IQR] | 54 [40–61] | 47 [35–70] |
| Male sex at birth, n (%) | 87 (88%) | 50 (33%) |
| Ethnicity, n (%) | ||
| white/Caucasian | 69 (69%) | 78 (51%) |
| Black | 5 (5%) | 1 (0.7%) |
| Asian | 10 (10%) | 59 (38%) |
| Latin American | 8 (8%) | 4 (2.6%) |
| Middle Eastern/Arab | 3 (3%) | 0 (0%) |
| Mixed ethnicity | 3 (3%) | 8 (5.3%) |
| Not disclosed | 1 (1%) | 2 (1.3%) |
| Number of chronic health conditions, median [IQR] | 0 [0–1] | 0 [0–1] |
| Hypertension, n (%) | 15 (15%) | 22 (14.5%) |
| Diabetes, n (%) | 6 (6%) | 6 (3.9%) |
| Asthma, n (%) | 7 (7%) | 15 (9.9%) |
| Obesity, n (%) | 15 (15%) | 14 (9.2%) |
| Chronic lung disease, n (%) | 4 (4%) | 3 (2%) |
| Chronic liver disease, n (%) | 4 (4%) | 1 (0.7%) |
| Chronic kidney disease, n (%) | 1 (1%) | 1 (0.7%) |
| Chronic heart disease, n (%) | 1 (1%) | 4 (2.6%) |
| Chronic blood disease, n (%) | 1 (1%) | 2 (1.3%) |
| Cancer, n (%) | 4 (4%) | 4 (2.6%) |
| Immunosuppression, n (%) | 3 (3%) | 0 (0%) |
| At least one of the above, n (%) | 45 (45%) | 50 (33%) |
| COVID-19 status | ||
| COVID-19 convalescent (anti-N Ab+) at study entry, n (%) | 8 (8%) | 15 (10%) |
| COVID-19 post-vaccination | 18 (18%) | 13 (9%) |
| Vaccine details | ||
| Initial two-dose regimen | ||
| mRNA - mRNA | 82 (82%) | 148 (97%) |
| ChAdOx1 - mRNA (heterologous) | 8 (8%) | 3 (2%) |
| ChAdOx1- ChAdOx1 | 8 (8%) | 1 (0.7%) |
| ChAdOx1 - not disclosed | 1 (1%) | - |
| Time between first and second doses in days, median [IQR] | 58 [53–67] | 89 [65–98] |
| Third dose | ||
| BNT162b2 | 23 of 80 (29%) | 55 of 134 (41%) |
| mRNA-1273 | 56 of 80 (70%) | 79 of 134 (59%) |
| Unknown | 1 of 80 (1%) | - |
| Time between second and third doses in days, median [IQR] | 183 [143–191] | 198 [173–216] |
| Specimen collection | ||
| Specimen one month after second dose, n (%) | 97 (97%) | 151 (99%) |
| Day of collection one month after second dose, median [IQR] | 30 [29–30] | 30 [29–32] |
| Specimen three months after second dose, n (%) | 96 (96%) | 148 (97%) |
| Day of collection three months after second dose, median [IQR] | 90 [90–91] | 90 [89–91] |
| Specimen six months after second dose, n (%) | 62 (62%) | 136 (89%) |
| Day of collection six months after second dose, median [IQR] | 180 [177–182] | 180 [178–182] |
| Specimen one month after third dose, n (%) | 80 (80%) | 134 (88%) |
| Day of collection one month after third dose, median [IQR] | 30 [30–32] | 30 [29–32] |